Results 141 to 150 of about 700,178 (349)

Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]

open access: yes, 2017
Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat   +6 more
core   +3 more sources

Coronary Slow Flow and No‐Reflow During Percutaneous Coronary Intervention: Contemporary Insights Into Imaging‐Guided Prediction, Prevention, and Management

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Coronary slow flow (SF) and no‐reflow (NR) are clinically significant complications of percutaneous coronary intervention (PCI), particularly in ST‐segment elevation myocardial infarction (STEMI) and saphenous vein graft (SVG) interventions. Angiographically defined as impaired myocardial perfusion despite restored epicardial patency, SF/NR ...
Bharat Khialani   +5 more
wiley   +1 more source

Higher Platelet-to-Lymphocyte Ratio Is Associated With Worse Outcomes After Intravenous Thrombolysis in Acute Ischaemic Stroke

open access: yesFrontiers in Neurology, 2019
Objective: The platelet-to-lymphocyte ratio (PLR) is a new marker of atherosclerotic inflammation and has been identified as a predictive factor in cardiovascular diseases, but its significance in patients with acute ischaemic stroke (AIS) who have ...
Jing Xu   +6 more
semanticscholar   +1 more source

急性缺血性卒中静脉溶栓桥接血管内治疗的疗效和安全性 Efficacy and Safety of Intravenous Thrombolysis Bridging Endovascular Therapy for Acute Ischemic Stroke

open access: yesZhongguo cuzhong zazhi, 2019
目的 观察rt-PA静脉溶栓桥接血管内治疗急性缺血性卒中的临床疗效和安全性。 方法 回顾性纳入2017年1-12月郑州市第一人民医院神经重症科收治的前循环急性缺血性卒中患 者,按rt-PA静脉溶栓后是否桥接血管内治疗分为单纯静脉溶栓组和桥接治疗组。主要疗效结局为治 疗后3个月mRS评分,次要疗效结局为24 h、3 d和30 d的NI HSS评分。安全性结局为2 d症状性颅内出血及 其他部位出血、10 d全因死亡。 结果 共入组56例患者,平均年龄60.77±12.72岁,男性35例(62.5 ...
乐婷,娄萍,路青山
doaj   +1 more source

Multi‐Cohort Analysis Reveals Genetic Predispositions to Clonal Hematopoiesis as Mutation‐Specific Risk Factors for Stroke

open access: yesAdvanced Genetics, Volume 6, Issue 1, March 2025.
This study comprehensively evaluated the differential effect of clonal hematopoiesis (CH) mutations on the risk of various stroke subtypes and functional recovery. It shows that TET2 is associated with small vessel stroke possibly via a pro‐inflammatory pathway. Abstract Recent observational studies have found an association between Clonal Hematopoesis
Shuyang Lin, Yang E. Li, Yan Wang
wiley   +1 more source

Activatable smart contrast agents for photoacoustic imaging

open access: yesSmart Molecules, EarlyView.
This review highlights recent advances in smart activatable photoacoustic imaging (PAI) contrast agents, which dynamically modulate their optical properties in response to external stimuli or microenvironmental cues. It discusses their molecular design, activation mechanisms, biomedical applications, and future prospects for clinically tailored use ...
Donghyeon Oh   +5 more
wiley   +1 more source

Renal Dysfunction Is an Independent Risk Factor for Poor Outcome in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis: A New Cutoff Value [PDF]

open access: gold, 2017
Elyar Sadeghi‐Hokmabadi   +10 more
openalex   +1 more source

Interventional oncology in children: Where are we now?

open access: yesJournal of Medical Imaging and Radiation Oncology, EarlyView.
Abstract Paediatric Interventional Oncology (IO) lags behind adult IO due to a scarcity of specific outcome data. The suboptimal way to evolve this field is relying heavily on adult experiences. The distinct tumour types prevalent in children, such as extracranial germ cell tumours, sarcomas, and neuroblastoma, differ strongly from those found in ...
Premal Amrishkumar Patel   +1 more
wiley   +1 more source

Computed Tomography Angiography before Intravenous Thrombolysis Does Not Increase the Risk of Renal Dysfunction [PDF]

open access: diamond, 2013
P. Sobrino García   +10 more
openalex   +1 more source

Home - About - Disclaimer - Privacy